Cyclo Therapeutics Completes Last Patient In Phase 3 TransportNPC Trial Of Niemann-Pick Type C1
Portfolio Pulse from Benzinga Newsdesk
Cyclo Therapeutics has completed the enrollment of the last patient in its Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1. The trial is the most comprehensive study for NPC1 treatment, and topline data from the 48-week interim analysis of 104 patients is expected in H1 2025.
May 30, 2024 | 1:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cyclo Therapeutics has completed the last patient enrollment in its Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1. Topline data from the 48-week interim analysis is expected in H1 2025.
The completion of patient enrollment in a Phase 3 trial is a significant milestone for Cyclo Therapeutics. Investors may view this as a positive development, anticipating potential approval and market entry if the trial results are favorable.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100